Rare genetic coagulation disorder

Rare genetic coagulation disorders encompass a group of inherited bleeding conditions caused by deficiencies or dysfunction of one or more coagulation factors. Orphanet groups these disorders under the classification code ORPHA:183654 as an umbrella category that includes deficiencies of various clotting factors such as fibrinogen, factor II (prothrombin), factor V, factor VII, factor X, factor XI, factor XII, factor XIII, and combined factor deficiencies, among others. These conditions affect the blood's ability to form clots properly, leading to a range of bleeding manifestations that can vary from mild to life-threatening. The primary body system affected is the hematologic (blood) system, but consequences of impaired coagulation can involve virtually any organ. Key clinical features may include prolonged bleeding after injury or surgery, easy bruising, mucosal bleeding (such as nosebleeds and gum bleeding), heavy menstrual bleeding in women, joint bleeding (hemarthrosis), muscle hematomas, and in severe cases, intracranial hemorrhage or umbilical cord bleeding in neonates. The severity of symptoms generally correlates with the degree of factor deficiency. Treatment depends on the specific factor deficiency and may include replacement therapy with plasma-derived or recombinant clotting factor concentrates, fresh frozen plasma, cryoprecipitate, antifibrinolytic agents (such as tranexamic acid), and desmopressin in select cases. For some rare factor deficiencies, specific factor concentrates are available, while others rely on broader plasma-based products. Prophylactic treatment may be necessary for patients with severe deficiencies to prevent spontaneous bleeding episodes. Genetic counseling is recommended for affected families.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare genetic coagulation disorder